Literature DB >> 33770152

COVID-19 quarantine in chronic kidney disease patients: A focus on sarcopenia traits.

Heitor Siqueira Ribeiro1, Kenneth R Wilund2, Ricardo Moreno Lima1.   

Abstract

Entities:  

Year:  2021        PMID: 33770152      PMCID: PMC8257277          DOI: 10.1590/2175-8239-JBN-2020-0201

Source DB:  PubMed          Journal:  J Bras Nefrol        ISSN: 0101-2800


× No keyword cloud information.
Dear Editor, Recently, the Brazilian Journal of Nephrology (BJN) published a supplementary issue regarding the Coronavirus Disease 2019 (COVID-19) impact on clinical nephrology routine, with a special focus on people with chronic kidney disease (CKD)1. We congratulate the BJN for the initiative, as it will have a high impact on COVID-19 management for nephrology professionals. Nonetheless, we would like to call attention to a negligence about the COVID-19 quarantine impact on physical function and musculoskeletal health, which has not been introduced and discussed by the BJN. People with CKD usually have high levels of sedentary behavior, which increases across the stages of the disease. Wilkinson et al. observed that walking is the most popular form of physical activity of people with CKD2, so greater sedentary behavior is expected as a consequence of COVID-19 quarantine. Hence, losses in muscle mass and strength are also expected, which is known to negatively affect physical function in this population3. Moreover, Cheval et al. found that an increase in sedentary behavior during COVID-19 quarantine was associated with poorer physical health, mental health, and subjective vitality in general subjects4. Sarcopenia is defined by an age-related decline in muscle mass, strength, and physical function. It is known that people with CKD are at higher risk for sarcopenia, which is related to a systemic catabolic state, higher protein energy wasting, and other metabolic disorders5. As seen in Figure 1, quarantine-related muscular disuse and inadequate dietary intake may potentially increase sarcopenia signs among people with CKD, a population that already presents with reduced functional reserve.
Figure 1

COVID-19 quarantine and its association with sarcopenia in chronic kidney disease patients.

People with CKD not yet in hemodialysis (HD) may be experiencing an even greater impact from quarantine than HD patients. In general, HD patients are still attending their dialysis clinics for scheduled treatments, so social isolation may not have impacted their routines to the same extent. Conversely, non-dialysis CKD patients do not have the same constraints, and they are generally more physically active. Thus, quarantine and social isolation due to COVID-19 may have a greater impact on their current lifestyle. The duration of social distancing that will be required for high risk individuals is not known, but the longer it lasts, the greater the impact it will likely have on the development and progression of sarcopenia in people with CKD around the world. Related consequences could include increases in cardiovascular events, hospitalization, progression to renal failure, mortality, and poor prognosis for kidney transplants. Thus, the European Work Group on Sarcopenia in Older People (EWGSOP2)6 criteria should be used for screening and monitoring sarcopenia (Table 1), as well as SARC-F questionnaire in the absence of direct measures.
Table 1

Sarcopenia screening and cut-off points according to the european work group on sarcopenia in older people (Ewgsop2)

TestsCut-off points for menCut-off points for women
EWGSOP2 sarcopenia cut-off points for low strength
Handgrip Strength<27 kgf<16 kgf
Sit-to-stand>15s for five repetitions>15s for five repetitions
If low strength is confirmed, a probable sarcopenia is confirmed with muscle quantity
EWGSOP2 sarcopenia cut-off points for low muscle quantity
ASMM<20 kg<15 kg
ASMM/height2 <7.0 kg/m2 <6.0 kg/m2
If low muscle quantity is verified, sarcopenia is confirmed and severity is analyzed
EWGSOP2 sarcopenia cut-off points for low performance
Gait Speed≤0.8 m/s
Short Physical Performance Battery≤8 point score
Timed-Up and Go≥20 s
400m walk testNon-completion or ≥6 min for completion
If low performance is seen, severe sarcopenia is confirmed 

ASMM = Appendicular Skeletal Muscle Mass; EWGSOP2 = Revised European Work Group on Sarcopenia in Older People.

ASMM = Appendicular Skeletal Muscle Mass; EWGSOP2 = Revised European Work Group on Sarcopenia in Older People. Health professionals involved in the management of CKD need to consider strategies in order to mitigate the adverse effects of quarantine and social distancing on physical activity and musculoskeletal health. Exercise and nutrition interventions can potentially attenuate these adverse effects. Therefore, we encourage patients of all CKD stages to maintain or engage an active lifestyle, as well as adequate dietary intake during COVID-19 quarantine. To make these interventions safe and feasible, we recommend two guides: Coronavirus Disease 2019: Quick Diet and Nutrition Guide for Patients With Chronic Kidney Disease (https://www.jrnjournal.org/article/S1051-2276(20)30213-2/fulltext) and My Get Active Guide (http://move.bangor.ac.uk/get-active.php.en), both available in Portuguese and English versions.
  6 in total

Review 1.  Clinical relevance of sarcopenia in chronic kidney disease.

Authors:  Ranjani N Moorthi; Keith G Avin
Journal:  Curr Opin Nephrol Hypertens       Date:  2017-05       Impact factor: 2.894

2.  Prevalence and correlates of physical activity across kidney disease stages: an observational multicentre study.

Authors:  Thomas J Wilkinson; Amy L Clarke; Daniel G D Nixon; Katherine L Hull; Yan Song; James O Burton; Thomas Yates; Alice C Smith
Journal:  Nephrol Dial Transplant       Date:  2021-03-29       Impact factor: 5.992

3.  Relationships between changes in self-reported physical activity, sedentary behaviour and health during the coronavirus (COVID-19) pandemic in France and Switzerland.

Authors:  Boris Cheval; Hamsini Sivaramakrishnan; Silvio Maltagliati; Layan Fessler; Cyril Forestier; Philippe Sarrazin; Dan Orsholits; Aïna Chalabaev; David Sander; Nikos Ntoumanis; Matthieu P Boisgontier
Journal:  J Sports Sci       Date:  2020-10-29       Impact factor: 3.337

4.  Sarcopenia: revised European consensus on definition and diagnosis.

Authors:  Alfonso J Cruz-Jentoft; Gülistan Bahat; Jürgen Bauer; Yves Boirie; Olivier Bruyère; Tommy Cederholm; Cyrus Cooper; Francesco Landi; Yves Rolland; Avan Aihie Sayer; Stéphane M Schneider; Cornel C Sieber; Eva Topinkova; Maurits Vandewoude; Marjolein Visser; Mauro Zamboni
Journal:  Age Ageing       Date:  2019-01-01       Impact factor: 10.668

5.  COVID-19: a major cause of cachexia and sarcopenia?

Authors:  John E Morley; Kamyar Kalantar-Zadeh; Stefan D Anker
Journal:  J Cachexia Sarcopenia Muscle       Date:  2020-06-09       Impact factor: 12.910

6.  The Brazilian Society of Nephrology and the Covid-19 Pandemic.

Authors:  Andrea Pio de Abreu; Miguel Carlos Riella; Marcelo Mazza do Nascimento
Journal:  J Bras Nefrol       Date:  2020-08-26
  6 in total
  2 in total

1.  Recognizing the importance of physical activity on sarcopenia in chronic kidney disease.

Authors:  Thomas J Wilkinson; Heitor S Ribeiro
Journal:  Osteoporos Sarcopenia       Date:  2022-04-05

Review 2.  Post-COVID-19 rehabilitation: a special look at chronic kidney disease patients.

Authors:  Heitor S Ribeiro; Amanda E Rodrigues; Jennifer Cantuária; Antônio Inda-Filho; Paul N Bennett
Journal:  Ren Replace Ther       Date:  2021-06-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.